Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Application of Breast Blood-oxygen Functional Imaging Technology

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2012 by Tianjin Medical University Cancer Institute and Hospital
Sponsor:
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier:
NCT01678170
First received: August 30, 2012
Last updated: December 21, 2015
Last verified: May 2012
  Purpose
This trial is going to evaluate the value of blood-oxygen functional imaging technology in the diagnosis of breast diseases.

Condition
Breast Diseases

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Clinical Application of Breast Blood-oxygen Functional Imaging Technology

Resource links provided by NLM:


Further study details as provided by Tianjin Medical University Cancer Institute and Hospital:

Estimated Enrollment: 200
Study Start Date: September 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Female with breast lump, received breast ultrasound and mammography
Criteria

Inclusion Criteria:

  • female older than 18 years breast lump received breast ultrasound and mammography

Exclusion Criteria:

  • After core-needle biopsy or resection After neoadjuvant chemotherapy, radiotherapy or endocrine therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01678170

Contacts
Contact: Peifang Liu, M.D. +86-22-23524536 cjr.liupeifang@vip.163.com

Locations
China, Tianjin
Department of Breast Imaging, Tianjin Medical University Cancer Hospital Recruiting
Tianjin, Tianjin, China, 300060
Contact: Peifang Liu, M.D.    +86-22-23524536    cjr.liupeifang@vip.163.com   
Sponsors and Collaborators
Tianjin Medical University Cancer Institute and Hospital
Investigators
Principal Investigator: Peifang Liu, M.D. Department of Breast Imaging, Tianjin Medical University Cancer Hospital
  More Information

Responsible Party: Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier: NCT01678170     History of Changes
Other Study ID Numbers: CIH-LPF-201205001 
Study First Received: August 30, 2012
Last Updated: December 21, 2015
Health Authority: China: Food and Drug Administration

Keywords provided by Tianjin Medical University Cancer Institute and Hospital:
blood-oxygen functional imaging technology
diagnosis

Additional relevant MeSH terms:
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 26, 2016